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Purpose: BOL-303242-X is a novel selective glucocorticoid receptor agonist under clinical evaluation for the treatment
of inflammatory skin and eye diseases. Data from in vitro and in vivo studies suggest an improved side-effect profile of
this compound compared to classical glucocorticoids. The aim of this study was to determine the anti-inflammatory effect
of BOL-303242-X in ocular cells.
Methods: Four primary human ocular cell cultures, including human conjunctival fibroblasts (HConFs), human corneal
epithelial cells (HCEpiCs), human optic nerve astrocytes (HONAs), and human retinal endothelial cells (HRECs), as well
as a human monocytic cell line, THP-1, were challenged with either lipopolysacharide (LPS) or interleukin-1ß (IL-1ß).
Luminex technology was used to determine the effect of BOL-303242-X on LPS- or IL-1ß-induced cytokine release and
intercellular adhesion molecule-1 (ICAM-1) levels. Effects of BOL-303242-X on nuclear factor kappa B (NFκB) and
mitogen-activated protein kinase (MAPK) in HCEpiCs were also assessed by measuring inhibitory kappa B protein-α
(IκB-α), phosphorylated p65 NFκB, and MAPK levels by western blotting. Dexamethasone (DEX) or triamcinolone
acetonide (TA) was used as the control.
Results: LPS or IL-1ß induced multiple cytokine release in all cell types studied. BOL-303242-X significantly reduced
LPS- or IL-1ß-induced inflammatory cytokine release in a dose-dependent manner, including granulocyte colony-
stimulating factor (G-CSF), IL-1ß, IL-6, IL-8, IL-12p40, monocyte chemotactic protein-1 (MCP-1), and tumor necrosis
factor-α (TNF-α). BOL-303242-X showed activity and potency comparable to that observed for DEX or TA. A statistically
significant inhibitory effect of BOL-303242-X was observed at doses ranging from 1 to 100 nM in HConFs, HCEpiCs,
HONAs, and THP-1. The IC50 values for these effects were in the low nM range. BOL-303242-X also significantly reduced
LPS-induced  IL-1ß  release  and  ICAM-1  levels  in  HRECs.  Furthermore,  BOL-303242-X  inhibited  IL-1ß-induced
decreases in IκB-α levels, as well as IL-1ß-induced phosphorylation of NFκB, p38, and c-Jun-N-terminal kinase (JNK)
MAPKs in HCEpiCs.
Conclusions: BOL-303242-X acts as a potent anti-inflammatory agent in various primary human ocular cells with similar
activity and potency compared to classical steroids. Results also suggest that MAPK (p38 and JNK) and NFκB signaling
pathways are involved in the anti-inflammatory properties of BOL-303242-X in HCEpiCs. An improved side effect profile
of this novel SEGRA compound has been reported recently. Thus, BOL-303242-X may provide a new option for the
treatment of ophthalmic conditions with an inflammatory component.
Activation of inflammatory pathways is a common tissue
response  to  external  pathogens  and  tissue  damage.
Inflammatory  processes  have  been  implicated  in  a  wide
variety of ocular diseases, including dry eye [1], allergy [2,
3],  diabetic  eye  disease  [4],  and  age-related  macular
degeneration  [5].  The  role  of  transcription  factors  in
modulating inflammatory processes is well known; in fact,
glucocorticoid receptor modulators such as dexamethasone
and  prednisolone  are  among  the  most  widely  prescribed
ocular  therapeutics  [6].  However,  the  use  of  steroids  in
ophthalmology is often associated with unwanted side effects
[7,8]. Therefore, identification of new agents with reduced
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undesirable effects continues to represent a substantial unmet
medical need.
It  is  believed  that  most  side  effects  of  steroids  are
mediated  via  transactivation-dependent  gene  regulation,
whereas  their  anti-inflammatory  properties  are  mediated
largely via transrepression [9,10]. Unwanted side effects of
the classical steroids used in ophthalmology correspond to the
elevation of intraocular pressure (IOP) and cataract formation
[7,11-13].  Selective  glucocorticoid  receptor  agonists
(SEGRAs) represent a set of molecules that preferentially
regulate  glucocorticoid  receptor-mediated  gene  expression
via  transrepression  and  carry  out  glucocorticoid-like  anti-
inflammatory activities. These agents may offer a reduced
side-effect profile in comparison with classical steroids [9,
14,15].
BOL-303242-X (also known as ZK 245186) is a novel
SEGRA compound under clinical evaluation for the treatment
of inflammatory skin and eye diseases [16]. This compound
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2606belongs to the pentanolamine series of topical SEGRAs [17],
and is not a steroid. It is also structurally and mechanistically
unique and different from the non-steroidal anti-inflammatory
drugs.  In  irritant  contact  dermatitis  and  T  cell-mediated
contact  allergy  models,  BOL-303242-X  showed  anti-
inflammatory efficacy after topical application similar to the
classical glucocorticoids. However, it exhibited a better safety
profile with regard to growth inhibition and induction of skin
atrophy  after  long-term  topical  application,  thymocyte
apoptosis,  hyperglycemia,  and  hepatic  tyrosine
aminotransferase activity [16]. In ophthalmology, recent data
suggest a reduced ability for BOL-303242-X to increase IOP
in normotensive rabbits when compared to dexamethasone
[18]. A recent study also demonstrated that BOL-303242-X
behaves as a partial agonist at increasing myocilin protein
levels and gene expression in monkey trabecular meshwork
cells [19]. Myocilin has been proposed to have an etiological
role in steroid-induced glaucoma [20,21]. These data indicate
that there is the potential for BOL-303242-X to provide a
better  safety  profile  than  classical  glucocorticoids  when
treating  chronic  inflammation  in  ocular  tissues.  A
comprehensive evaluation of the effect of this novel SEGRA
compound on inflammatory mediators, including cytokines
and adhesion molecules, in key ocular tissues has not been
performed to date. Therefore, the objective of these studies
was  to  determine  the  anti-inflammatory  properties  of
BOL-303242-X, on the release of important inflammatory
cytokines in cultured primary human conjunctival fibroblasts
(HConFs), human corneal epithelial cells (HCEpiCs), human
optic  nerve  astrocytes  (HONAs),  and  human  retinal
endothelial  cells  (HRECs).  The  responsiveness  of  the
monocytic cell line THP-1 to inflammatory challenges was
also studied as a systemic benchmark. Levels of intercellular
adhesion  molecule-1  (ICAM-1;  a  vascular  endothelial
inflammatory  marker),  were  also  measured  in  HRECs.
Finally, to explore the potential signaling cascades involved
in  the  anti-inflammatory  action  of  this  novel  SEGRA
compound, the effects of BOL-303242-X on the inflammatory
transcription factor NFκB and MAPK signaling cascade were
examined in HCEpiCs. MAPKs are serine/threonine-specific
protein  kinases  that  respond  to  extracellular  stimuli  and
regulate various cellular activities. JNK and p38 MAPKs have
been  implicated  as  playing  key  regulatory  roles  in  the
production of proinflammatory cytokines and downstream
signaling  events  leading  to  inflammation  and  tissue
destruction [22].
METHODS
Materials:  EpiLife  medium  and  human  corneal  growth
supplement  were  purchased  from  Cascade  Biologics
(Portland,  OR).  Fibroblast  Medium  and  fibroblast  growth
supplement were purchased from ScienCell (San Diego, CA).
CS-C medium and acidic fibroblast growth factor (aFGF)
were  purchased  from  Cell  Systems  (Kirkland,  WA).
RPMI-1640 medium and DMEM medium were purchased
from  Invitrogen  (Carlsbad,  CA).  Fetal  bovine  serum  was
purchased  from  Hyclone  (Logan,  UT).  Charcoal/Dextran-
treated fetal bovine serum (CD-FBS) and Micro BCA protein
assay  kit  were  purchased  from  Fisher  Thermo  Scientific
(Waltham,  MA).  Dexamethasone  (DEX),  triamcinolone
acetonide  (TA),  dimethyl  sulfoxide  (DMSO),
lipopolysaccharide (LPS), and proteinase inhibitor cocktail
were  from  Sigma  (St.  Louis,  MO).  BOL-303242-X  (ZK
245186;  R-1,1,1-trifluoro-4-(5-fluoro-2,3-
dihydrobenzofuran-7-yl)-4-methyl-2-{[(2-methyl-5-
quinolyl)amino]methyl}pentan-2-ol) was provided by Bayer
Schering Pharma (Berlin, Germany). IL-1ß was from R&D
Systems (Minneapolis, MN). Alamar Blue solution was from
Biosource (Camarillo, CA). Human multiplex-cytokine and
sICAM-1  Luminex  kits  were  obtained  from  Millipore
(Billerica, MA). Antibodies for the western blotting were
purchased from Cell Signaling Technology (Danvers, MA),
Santa Cruz Biotech (Santa Cruz, CA), Zymed (San Francisco,
CA), and Millipore. All other reagents were purchased from
standard commercial sources and were of the highest available
quality and purity.
Cells and cell treatments: Primary HCEpiCs were purchased
from Cascade Biologics and maintained in EpiLife medium
containing  human  corneal  growth  supplement  (bovine
pituitary  extract  0.2%  [v/v],  bovine  insulin  [5  µg/ml],
hydrocortisone [0.18 µg/ml], bovine transferrin [5 µg/ml], and
mouse epidermal growth factor [1 ng/ml]). Primary HConFs
were purchased from ScienCell and maintained in fibroblast
medium  (FM)  containing  fibroblast  growth  supplement
(undisclosed formulation) and 2% FBS. Primary HRECs were
purchased  from  Cell  Systems  and  maintained  in  CS-C
medium containing acidic fibroblast growth factor (aFGF)
and  10%  FBS.  THP-1  cells  were  purchased  from  ATCC
(Manassas,  VA)  and  maintained  in  RPMI-1640  medium
containing  10%  FBS.  HONAs  were  isolated  according  to
Yang  &  Hernandez  [23],  characterized  by
immunocytochemistry using anti-glial fibrillary acidic protein
(GFAP) antibody with 90–95% positive cells, and maintained
in astrocyte defined serum-free medium (ADSF) containing
3% CD-FBS and G5 astrocyte supplement (insulin [5 ng/ml],
human transferrin [50 ng/ml], selenite [5.2 pg/ml], biotin [10
pg/ml], hydrocortisone [3.6 pg/ml], FGF [5 pg/ml], and EGF
[10 pg/ml]). These cells were all cultured in the above media,
containing  100  U/ml  of  penicillin  and  100  µg/ml  of
streptomycin, at 37 °C in a humidified incubator with 5%
CO2. Prior to treatments, cells were seeded in 24-well plates
and cultured until confluence. Cells were pretreated with test
agents (BOL-303242-X, DEX, or TA) for 2 h, and then further
treated  with  either  vehicle  (0.1%  DMSO),  LPS,  IL-1ß,
BOL-303242-X, DEX, TA, or combinations of them in basal
medium (HCEpiCs and HONAs) or in basal medium plus CD-
FBS (HConF, HREC, and THP-1) for 18 h. Each treatment
was performed in triplicate. After conditioned media were
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for the Alamar Blue assay. For the ICAM-1 and IL-1ß assays
of  HRECs,  cells  were  lysed  in  NP-40  lysis  buffer  (PBS
containing  0.1%  NP-40  and  10  µl/ml  proteinase  inhibitor
cocktail), transferred to Eppendorf tubes, and sonicated. After
centrifugation at 10,000× g for 5 min, the supernatant from
each triplicate sample was transferred to a fresh Eppendorf
tube  for  IL-1ß  and  ICAM-1  Luminex  and  protein
measurements.
Multiplex  Luminex  technology:  Cytokine  content  in  the
culture medium or cell lysate was analyzed using multiplex
Luminex technology [24-26]. Up to 26 cytokines (Eotaxin;
Fractalkine;  G-CSF;  granulocyte  macrophage  colony-
stimulating factor [GM-CSF]; IL-1α; IL-1β; IL-2; IL-3; IL-4;
IL-5; IL-6; IL-7; IL-8; IL-10; IL-12(p40); IL-12(p70); IL-13;
IL-15;  IFN-γ;  interferon-inducible  protein-10  [IP-10];
MCP-1;  macrophage  inflammatory  protein-1β  [MIP-1α];
transforming  growth  factor-α  [TGF-α];  TNF-α,  regulated
upon  activation,  normal  T-cell  expressed,  and  secreted
[RANTES]; and vascular endothelial growth factor [VEGF])
were measured according to the manufacturer's instructions.
Data were analyzed using a Luminex 200 (Luminex, Austin,
TX) and Beadview software v1.0 (Upstate Cell Signaling
Solutions,  Temecula,  CA).  Standard  curves  for  known
concentrations of recombinant human cytokines were used to
convert median fluorescence intensities (MFI) to cytokine
concentrations  in  pg/ml.  Only  the  linear  portions  of  the
standard  curves  were  used  to  quantify  cytokine
concentrations,  and  in  instances  where  the  fluorescence
reading exceeded the linear range of the standard curve, an
appropriate  dilution  was  performed  to  ensure  that  the
concentration was in the linear portion of the curve. IL-1ß and
ICAM-1 concentrations in the cell lysate were normalized
based on the protein content of the sample and expressed as
pg/mg protein.
Western blot analysis for IκB-α, NFκB, and MAPKs: Cells
were pretreated with vehicle, BOL-303242-X or DEX for 2 h,
and then further treated with vehicle, IL-1ß, or either IL-1ß
plus BOL-303242-X or DEX in basal EpiLife medium for 10
min or 30 min. Cells were washed with ice-cold PBS and lysed
in cell lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% sodium
dodecyl sulfate [SDS], 10% glycerol, and 1:1,000 proteinase
inhibitor cocktail). Cells were sonicated, and centrifuged at
12,000 rpm. Protein concentration was determined using the
Micro BCA protein assay kit. Proteins in aliquots of cell lysate
(approximately  30  µg  protein)  were  separated  by  SDS-
polyacrylamide electrophoresis (SDS-PAGE) on 10% gels
and  transferred  to  nitrocellulose  membranes.  Membranes
were  blocked  with  1%  BSA  and  exposed  to  rabbit  anti-
phospho-p38  (Thr180/Tyr182)  antibody  (Cell  Signaling),
rabbit  anti-phospho-p65  NFκB  (Ser536)  antibody  (Cell
Signaling), rabbit anti-IκB-α antibody (Santa Cruz Biotech),
or rabbit anti-phospho-JNK (Thr183/Tyr185) antibody (Santa
Cruz  Biotech).  The  blots  were  washed,  and  exposed  to
horseradish  peroxidase-conjugated  anti-rabbit  secondary
antibody. After washing, blots were incubated in enhanced
chemiluminescence solutions and chemiluminescent bands
were visualized using the FluorChem imaging system (Alpha
Innotech, San Leandro, CA) [25]. Blots were then stripped
and re-probed as appropriate with rabbit anti-p38 antibody
(Cell  Signaling),  rabbit  anti-JNK  antibody  (Santa  Cruz),
rabbit anti-p65 NFκB antibody (Cell Signaling), or mouse
anti-keratin K3/K76 antibody (Millipore; a specific marker of
corneal epithelial cells), as loading controls. The experiment
was repeated three to four times. Analysis of western blot band
density  for  phosphorylated  and  non-phosphorylated  p65
NFκB, JNKs, and p38, as well as keratin K3/K76 in captured
digital images, was done using the Alpha-Innotech Chemi-
Imager software (Alpha Innotech). Levels of phosphorylated
p65  NF-κB,  JNKs,  and  p38  were  normalized  to  non-
phosphorylated p65 NF-κB, JNKs, and p38 from the same
sample on the same membrane. Levels of IκB-α protein were
normalized  to  keratin  K3/K76.  For  quantitation  of  JNK
phosphorylation, the densities of two JNK isoforms, JNK1 (46
kDa) and JNK2/3 (54 kDa), were determined separately and
then summed together. The experiment was repeated three to
four times.
Cellular metabolic activity: Cellular metabolic activity was
determined  by  the  Alamar  Blue  assay  [27].  Briefly,  after
removal of medium, cells were incubated with 1:10 diluted
Alamar Blue solution for 3 h at 37 °C in a humidified incubator
with  5%  CO2.  The  plate  was  read  fluorometrically  by
excitation at 530–560 nm and emission at 590 nm. Relative
fluorescence  units  (RFU)  were  used  to  determine  cell
metabolic activity.
Data analysis and statistics: Data were expressed as means
±SEM unless otherwise indicated. Statistical analysis was
conducted  after  evaluating  the  data  for  compliance  with
normality and variance homogeneity criteria. If these criteria
were not met, data were Box-Cox-transformed and then the
analysis was completed on the transformed data. Comparison
of treatment effects across groups was performed using two-
way analysis of variance (ANOVA) followed by the Tukey-
Kramer test (JMP 7 software, SAS Institute, Cary, NC) on
either raw or Box-Cox-transformed data [28,29] using either
LPS or IL-1ß treatment as a reference. For all assays, a p≤0.05
was predetermined as the criterion of statistical significance.
A Student’s t-test on either raw or Box-Cox-transformed data
[28,29] was used to determine whether LPS or IL-1ß was
effective  at  increasing  cytokine  release  compared  to  the
vehicle control. Dose-response curve data were fitted to a re-
parameterized four-parameter logic equation [30], and this
equation, below, permitted estimation of the IC50 values for
each drug treatment.
y   = Min +   (Max - Min) /(1 +   eSlope . logEC50 – log10(X) )
Where Max is maximal response, Min is minimal response,
e is base for natural logs, slope is the Hill Coefficient • natural
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the base 10 log of dose.
Statistical analysis of western blot data was performed
using one-way ANOVA followed by the Dunnett’s test on
either raw or Box-Cox-transformed data, and a p≤0.05 was
considered statistically significant. For all the experiments,
the specific transformations used are described in the figure
legends.
RESULTS
BOL-303242-X  demonstrates  activity  similar  to  classical
glucocorticoids in inhibiting LPS- or IL-1ß-induced cytokine
release in four different primary human ocular cells: HConFs,
HCEpiCs, HONAs, and HRECs were pretreated with the test
agents,  BOL-303242-X,  dexamethasone  (DEX),  or
triamcinolone acetonide (TA), for 2 h, and then further treated
with vehicle, LPS, IL-1ß, test agents, LPS plus test agents, or
IL-1ß plus test agents for 18 h. No statistically significant
effects  of  BOL-303242-X  or  dexamethasone  on  cellular
metabolic activity, an index of cell viability, were observed in
the four cell types studied. Under basal conditions (without
LPS or IL-1ß stimulation), cytokine levels in the conditioned
medium were very low, with almost all the cytokines studied
below  the  limits  of  detection  by  Luminex  technology.
Furthermore, no statistically significant effect on cytokine
release from either BOL-303242-X or the two glucocorticoids
was observed.
BOL-303242-X  significantly  inhibited  G-CSF,  IL-6,
IL-8, and MCP-1 release from HConFs at doses of 1–100 nM
in  a  dose-dependent  manner  (Figure  1).  The  effects  of
BOL-303242-X were similar to those of DEX, with estimated
IC50 values of 1 nM for DEX versus 7 nM for BOL-303242-
X with G-CSF, 5 nM for DEX versus 2 nM for BOL-303242-
X with IL-6, 10 nM for DEX versus 4 nM for BOL-303242-
X  with  IL-8,  and  18  nM  for  DEX  versus  7  nM  for
BOL-303242-X with MCP-1. The differences observed in
IC50 between BOL-303242-X and DEX were not considered
statistically significant because confidence limits on these
values overlapped for all cytokines tested. Furthermore, a
significantly higher activity of BOL-303242-X was observed
when compared to DEX at the 1 nM, 10 nM, 1 µM, and 10
µM doses with IL-6 (Figure 1). In addition, there was a greater
inhibition of MCP-1 release by BOL-303242-X as compared
to DEX at 10 µM (Figure 1). Together, these data demonstrate
the full anti-inflammatory properties of BOL-303242-X in
HConFs.
In  HCEpiCs,  BOL-303242-X  significantly  inhibited
IL-1β-induced IL-6 release at 10 nM and TNF-α release at 100
nM, in a dose-dependent manner (Figure 2). Whereas at lower
doses,  DEX  induced  significantly  greater  effects  than
BOL-303242-X for TNF-α, both compounds showed similar
activity at reducing IL-6 and TNF-α levels at the highest doses
tested (Figure 2), indicating the full agonist activity of the
compound as an anti-inflammatory agent.
In HONAs, both BOL-303242-X and TA inhibited LPS-
induced IL-6 and IL-8 release, and a statistically significant
inhibitory effect on IL-6 and IL-8 was observed at doses as
low as 10 nM (Figure 3). At this dose, the activity of both
compounds was very close to maximal, making it difficult to
estimate IC50 values (<10 nM). In HONAs, BOL-303242-X
behaved as a full anti-inflammatory agent, with efficacies
comparable  to  those  observed  for  TA  in  these  cytokines
(Figure 3), as seen in HConFs and HCEpiCs.
BOL-303242-X  and  TA  both  inhibited  LPS-induced
increases in cellular levels of IL-1ß and ICAM-1 in HRECs,
and  a  statistically  significant  reduction  of  LPS-induced
increases in the cellular levels of IL-1ß and ICAM-1 was
observed at doses ranging from 0.1 to 10 µM (Figure 4).
BOL-303242-X  reduces  LPS-induced  cytokine  release  in
THP-1  cells:  Monocytes  play  a  critical  role  in  the
inflammatory process; therefore, the effect of BOL-303242-
X on cytokine release in human THP-1 monocytes was also
evaluated.  Both  BOL-303242-X  and  DEX  inhibited  LPS-
induced  IL-6,  IL-12p40,  and  MCP-1  release  in  a  dose-
dependent manner, and a statistically significant inhibitory
effect on IL-6, IL-12p40, and MCP-1 release was observed at
1 nM (Figure 5). DEX was slightly more efficacious than
BOL-303242-X  (86%  compared  to  DEX  for  IL-6,  75%
compared to DEX for IL-12p40, and 93% compared to DEX
for MCP-1). However, the estimated IC50s for both drugs with
these cytokines were comparable (2 nM for DEX versus 2 nM
for BOL-303242-X with IL-6, 2 nM for DEX versus 2 nM for
BOL-303242-X with IL-12p40, and 1 nM for DEX versus 1
nM for BOL-303242-X with MCP-1). Again, the differences
observed in IC50 between BOL-303242-X and DEX were not
considered statistically significant because confidence limits
on these values overlapped for all cytokines tested.
BOL-303242-X reduces MAPK phosphorylation/activation in
HCEpiCs:  To  investigate  the  potential  mechanisms
underlying the anti-inflammatory activity of BOL-303242-X,
its effects on the MAPKs p38 and JNK were determined in
HCEpiCs. Immunoblotting was performed using phospho-
specific  antibodies  against  JNKs  at  Thr183/Tyr185,  and
against  p38  at  Thr180/Tyr182.  These  sites  have  been
demonstrated to be associated with the activation state of these
proteins [31]. Treatment of HCEpiCs with IL-1β for 30 min
significantly increased the phosphorylation state of JNK and
p38 MAP kinases (Figure 6). IL-β-induced phosphorylation
of p38 and JNKs was significantly reduced by BOL-303242-
X or DEX at both 1 µM and 10 µM doses (Figure 6). The
activity of both compounds was comparable (107% compared
to DEX at 1 µM [100%] for p38, 128% compared to DEX at
10 µM [100%] for p38, 121% compared to DEX at 1 µM
[100%] for JNKs, and 126% compared to DEX at 10 µM
[100%] for JNKs).
BOL-303242-X reduces NFκB phosphorylation and increases
levels of IkB in HCEpiCs: The effect of BOL-303242-X on
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measuring  NFκB  phosphorylation  and  IκB-α  degradation.
Treatment of HCEpiCs with IL-1β for 10 min significantly
increased the phosphorylation state of p65 NFκB at Ser536, a
site that has been demonstrated to be associated with NFκB’s
activation  state  [32,33].  Under  basal  conditions,  NFκB  is
prevented from entering the nucleus by its interaction with
IκB; therefore, a key step in the activation of NFκB is the
degradation of IkB [33]. After IL-1β treatment, there was a
significant decrease in cellular IκB-α levels, consistent with
IκB-α degradation. IL-β-induced p65 NFκB phosphorylation
at Ser536 was significantly reduced by 10 µM BOL-303242-
X and both 1 µM and 10 µM DEX (Figure 7). Moreover, 10
µM  BOL-303242-X  and  DEX  significantly  increased  the
levels of IκB-α in the cell lysate (Figure 7). These effects
would be expected to result in an effective reduction of the
ability of NFkB to induce inflammation by combining these
two  mechanisms;  i.e.,  there  would  be  reduction  of
transcription factor phosphorylation and elevation of levels of
the inhibitor IκB.
DISCUSSION
Inflammation  is  a  local,  generally  non-specific,  defensive
response  to  tissue  damage  caused  by  physical,  chemical,
immunological,  or  microbial  stimuli  [34].  Whereas
inflammation is a physiological response, and in general is
beneficial, excessive or chronic inflammatory processes result
in tissue destruction and disease states. Among the various
therapeutic  agents  that  have  been  used  to  modulate
inflammatory  processes  [35],  glucocorticoids  have  been
successfully used for the past 50 years [7]. The disorders
commonly receiving glucocorticoid treatment include acute
and  chronic  ophthalmic  conditions  with  an  inflammatory
component such as dry eye [1], allergy [2,3], conjunctivitis
[36],  anterior  uveitis  [37],  postoperative  infection  and
inflammation  [38],  and  diabetic  eye  disease  [4,39-43].
However, the use of these synthetic and potent glucocorticoids
in ophthalmology is limited by undesirable side effects, such
as  cataract  formation  and  intraocular  pressure  elevations
[11,12]. These ocular side effects are associated particularly
with the long-term use of these agents [11,12].
Figure 1. BOL-303242-X demonstrates
similar  activity  as  dexamethasone
(DEX)  in  reducing  IL-1ß-induced
cytokine  release  from  human
conjunctival  fibroblasts.  Cells  were
pretreated with BOL-303242-X or DEX
for 2 h, and then further treated for 18 h
with  vehicle  (0.1%  DMSO),  IL-1ß,
BOL-303242-X, DEX, or combinations
of  them.  Cytokine  content  in  the
conditioned media was determined by
Luminex.  Data  are  means±SEM  or
geometric means±SE estimated by the
Taylor Series expansion for the MCP-1
data;  n=3.  The  asterisk  indicates  a
p≤0.05 versus that for IL-1ß. The dagger
indicates a p≤0.05 versus BOL-303242-
X  at  same  concentration.  Statistical
analysis was performed using two-way
ANOVA  followed  by  the  Tukey-
Kramer test on raw data for G-CSF and
IL-8. Data were elevated to the power of
0.4 for IL-6 and by taking the logarithm
of MCP-1 data. A Student’s t-test was
used to determine whether IL-1ß was
effective at increasing cytokine release.
The solid bar is statistically significant
versus  the  gray  bar  at  increasing
cytokine release.
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2610SEGRAs represent a new class of glucocorticoid receptor
modulators. These agents cause the glucocorticoid receptor to
adopt  a  conformation  such  that  the  transcription  complex
preferentially  supports  transrepression-mediated  anti-
inflammatory  effects  over  the  transactivation-mediated
effects [9,17,44,45]. Since most of the steroid-associated side
effects  are  thought  to  be  due  to  transactivation-mediated
activities of the glucocorticoid receptor, SEGRA compounds
are  expected  to  be  safer  than  classical  glucocorticoids.  A
recent study has shown that ZK 245186 (BOL-303242-X) is
a potent anti-inflammatory agent for the topical treatment of
inflammatory skin diseases, and it has demonstrated fewer
side effects than classical glucocorticoids [16]. Data from our
group also suggest that BOL-303242-X offers an improved
ocular  side  effect  profile.  Myocilin  is  a  protein  normally
detected  in  the  trabecular  meshwork  [46,47].  It  has  been
reported that glucocorticoids increase myocilin expression in
trabecular meshwork cells, and that this protein may have an
Figure 2. BOL-303242-X demonstrates
similar  activity  as  dexamethasone
(DEX)  in  reducing  IL-1ß-induced
cytokine  release  from  human  corneal
epithelial  cells.  Cells  were  pretreated
with BOL-303242-X or DEX for 2 h,
and  then  further  treated  with  vehicle
(0.1% DMSO), IL-1ß, BOL-303242-X,
DEX, or combinations of them for 18 h.
Cytokine  content  in  the  conditioned
media  was  determined  by  Luminex.
Data are means±SEM; n=3. The asterisk
indicates a p≤0.05 versus IL-1ß, and the
dagger  indicates  a  p≤0.05  versus
BOL-303242-X  at  the  same
concentration.  Statistical  analysis  was
performed  using  two-way  ANOVA
followed by the Tukey-Kramer test on
raw data. A Student’s t-test was used to
determine whether IL-1ß was effective.
The solid bar is statistically significant
versus  the  gray  bar  at  increasing
cytokine release.
Figure 3. BOL-303242-X demonstrates
similar  activity  as  triamcinolone
acetonide  (TA)  in  reducing  LPS-
induced cytokine release in human optic
nerve astrocytes. Cells were pretreated
with BOL-303242-X or TA for 2 h, and
then further treated with vehicle (0.1%
DMSO), LPS, BOL-303242-X, TA, or
combinations of them at the indicated
doses for 18 h. Cytokine content in the
conditioned media was determined by
Luminex. Data are means±SEM; n=3.
The asterisk indicates a p≤0.05 versus
LPS.  The  dagger  indicates  a  p≤0.05
versus TA at the same concentration.
Statistical analysis was performed using
two-way  ANOVA  followed  by  the
Tukey-Kramer  test  on  raw  data.  A
Student’s t-test was used to determine
whether LPS was effective at increasing
cytokine  release.  The  solid  bar  is
statistically significant versus the gray
bar.
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2611etiological role in steroid-induced glaucoma [20,21]. We have
found  that  BOL-303242-X  behaves  as  a  partial  agonist
compared  both  to  dexamethasone  at  increasing  myocilin
protein levels and to the gene expression of cultured monkey
trabecular meshwork cells [19,48]. These data suggest that
BOL-303242-X may offer a better side-effect profile than
glucocorticoids when looking at IOP elevations. This has been
evaluated in in vivo animal studies, which indicated a reduced
ability for the compound to increase IOP in normotensive
rabbits when compared to dexamethasone [18].
Although  the  glucocorticoid  action  in  inflammatory
diseases is not fully understood, it is well documented that
glucocorticoids inhibit the transcription of the majority of
inflammatory  cytokines  and  chemokines  involved  in  the
inflammatory process, including eotaxin, GM-CSF, IL-1ß,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-11, MCP-1, MIP-1,
Figure 4. BOL-303242-X demonstrates
similar  activity  as  triamcinolone
acetonide  (TA)  in  reducing  LPS-
induced  IL-1ß  and  ICAM-1  levels  in
human retinal endothelial cell lysates.
Cells  were  pretreated  with
BOL-303242-X or TA for 2 h, and then
further  treated  with  vehicle  (0.1%
DMSO), LPS, BOL-303242-X, TA, or
combinations of them at the indicated
doses for 18 h. Cytokine and ICAM-1
content  in  the  cell  lysates  was
determined  by  Luminex,  and  protein
content in the lysates by the Micro BCA
assay. Data are means±SEM; n=3. The
asterisk indicates a p≤0.05 versus the
control,  and  the  dagger  indicates  a
p≤0.05 versus LPS. Statistical analysis
was performed using one-way ANOVA
followed by the Tukey-Kramer test on
raw data.
Figure 5. BOL-303242-X reduces LPS-induced cytokine release with similar activity as dexamethasone (DEX) from THP-1 cells. Cells were
pretreated with BOL-303242-X or DEX for 2 h, and then further treated with vehicle (0.1% DMSO), LPS, BOL-303242-X, DEX, or their
combinations at the indicated doses for 18 h. Cytokine content in the conditioned media was determined by Luminex. Data are means±SEM
or geometric means±SE estimated by the Taylor series expansion for the MCP-1 data; n=3. The asterisk indicates a p≤0.05 versus LPS. The
dagger indicates a p≤0.05 versus DEX at the same concentration. Statistical analysis was performed using two-way ANOVA followed by the
Tukey-Kramer test, and data elevated to the power of 0.4 for IL-6, 0.8 for IL-12p40, and by taking the logarithm of MCP-1 data. A Student’s
t-test was used to determine whether LPS was effective at increasing cytokine release. The solid bar is statistically significant versus the gray
bar.
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2612MIP-3, MIP-4, MIP-1α, RANTES, and TNF-α, in a variety of
cell types [10]. Glucocorticoids also have been shown to have
a  direct  inhibitory  effect  on  the  expression  of  adhesion
molecules such as ICAM-1 in endothelial cells and other cell
types [10]. Elevated levels of inflammatory cytokines on the
ocular surface have been reported in patients with dry eye and
allergies [1,2]. Increased levels of IL-1ß and TNF-α have been
detected in the serum and vitreous of patients with diabetic
retinopathy [43,49,50], and these cytokines have been shown
to  induce  inflammatory  responses  in  HRECs  [50].  In  the
current  study,  BOL-303242-X  inhibited  the  release  of
multiple cytokines after either an LPS or IL-1ß challenge in
four different ocular cell types (HConF, HCEpiC, HREC, and
HONA), including some key proinflammatory cytokines such
as IL-1ß, IL-6, IL-8, MCP-1, and TNF-α. More importantly,
the observed anti-inflammatory activity in these ocular cells
was  comparable  to  that  observed  for  two  classical
glucocorticoids, dexamethasone and triamcinolone acetonide,
in terms of efficacy and potency, when tested under the same
conditions.  Furthermore,  the  anti-inflammatory  effects
observed in the cultured ocular cells were comparable to those
observed in THP-1, a human monocytic cell line that has been
widely used to study cytokine expression and release.
The promoter or enhancer regions of most inflammatory
genes  do  not  contain  the  classical  GRE  that  are  part  of
glucocorticoid responsive genes [51]. Therefore, it is believed
that the transrepression-mediated anti-inflammatory effect of
glucocorticoids does not involve direct interaction between
glucocorticoid  receptors  and  the  promoter  regions  of
proinflammatory  genes.  Instead,  liganded  and  dimerized
glucocorticoid  receptors  interact  with  transcription  factors
such  as  NFκB  and  activator  protein-1  (AP-1),  as  well  as
several  other  cellular  signaling  molecules,  impairing  or
reducing  their  ability  to  increase  transcription  of
inflammatory  genes  [10,52,54].  Among  these  signaling
pathways,  mitogen-activated  protein  kinase  (MAPK)
cascades play a key role in the regulation of inflammatory
gene  expression  [7,10,51].  In  mammalian  cells,  three
distinguishable MAPK cascades have been identified so far,
consisting of the extracellular signal-regulated kinase 1 and 2
(ERK1/2),  which  preferentially  regulates  cell  growth  and
differentiation,  as  well  as  JNK  and  p38  MAPK,  which
function mainly in stress responses like inflammation and
apoptosis [22]. Glucocorticoids may inhibit AP-1 and NFκB
activities  via  JNKs,  which  are  known  to  activate  these
transcription factors [55,56]. Multiple inflammatory genes,
including  GM-CSF,  IL-1ß,  IL-6,  IL-8,  and  TNF-α,  are
Figure  6.  BOL-303242-X  and
dexamethasone  (DEX)  reduce  IL-1ß-
induced  JNK  and  p38  MAPK
phosphorylation  in  human  corneal
epithelial  cells.  Cells  were  pretreated
with vehicle, BOL-303242-X, or DEX
for 2 h, and then further treated with
vehicle, IL-1ß, IL-1ß plus BOL303242-
X, or DEX in basic EpiLife medium for
30  min.  Cell  lysates  were  prepared,
resolved  by  SDS-PAGE,  and  western
blotting was performed with phospho
and total p38 or JNK antibodies. The top
images  show  representative  western
blots for phosphorylated JNK (pJNK),
total JNK, phosphorylated p38 (pp38),
and total p38. At the bottom, the results
of  the  quantification  by  densitometry
and  phosphorylated:total  JNK  or  p38
ratios  are  shown  for  the  pJNK  (left
panel) and pp38 (right panel) blots. The
data are expressed as % of IL-β. Data are
means±SEM  from  three  to  four
independent experiments. The asterisk
indicates a p≤0.05 versus IL-1ß. One-
way ANOVA followed by the Dunnett’s
test on data elevated to the power of 0.8
for pJNK and on raw data for p38. In the
figure, BOL represents BOL-303242-X.
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2613regulated by p38 MAKP, which stabilizes their mRNA [57].
There  is  increasing  evidence  that  glucocorticoids  may
interfere  with  the  MAPK  cascades  via  mitogen-activated
protein  kinase  phosphatase  1  (MKP-1),  by  increasing  the
expression of the MKP-1 gene and attenuating proteasomal
degradation of MKP-1 [58].
A parallel pathway to activation of MAPK in response to
inflammatory signals involves a series of kinases. Activation
of these kinases leads to nuclear translocation of the NFκB.
There are multiple mechanisms by which glucocorticoids may
inhibit this transcription factor. Glucocorticoids can prevent
the binding of NFκB to its target DNA, repress the activity of
the  transcription  factor,  and/or  prevent  recruitment  of
coactivators required for its activity. NFκB activity can also
be  regulated  indirectly  through  increased  synthesis  of  its
inhibitor, IκB. Our data indicate that both BOL-303242-X and
dexamethasone  inhibit  IL-1ß-induced  reduction  in  IκB-α
levels  and  IL-1ß-induced  increase  in  p65  NFκB
phosphorylation.
In  summary,  as  an  anti-inflammatory  agent,
BOL-303242-X  is  potent  and  fully  efficacious  when
compared  with  classical  glucocorticoids.  The  compound
demonstrates dose-dependent inhibitory effects on LPS- or
IL-β-induced  multiple  inflammatory  cytokine  release  in
primary human ocular cell cultures, including conjunctival
fibroblasts, corneal epithelial cells, optic nerve astrocytes, and
retinal endothelial cells. Our observations, together with data
indicating  that  the  compound  acts  as  a  partial  agonist  to
increase myocilin protein and mRNA levels when incubated
with monkey trabecular meshwork cells [19], and that the
compound  shows  a  reduced  propensity  to  elevate  IOP  in
normotensive rabbits [18], suggest that this novel SEGRA
compound may be a new option for the treatment of chronic
inflammatory  conditions  of  the  eye,  and  may  provide  a
beneficial  side-effect  profile  in  comparison  with  classical
steroids.
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